13 Skin

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/5965.htm#_5965

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/5967.htm

Restrictions: Only to be prescribed via dermatology clinics.

Prescribing Notes:

A treatment dose of 30mg once daily is recommended and should only be reduced to 10mg once daily if not tolerated.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/201617.htm

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/PHP7735-psoriderm.htm?q=psoriderm&t=search&ss=text&p=1#PHP7735-psoriderm

Prescribing Notes:

This is not available as a licensed proprietary preparation, but is routinely available as a "special"

Prescribing Notes:

This is not available as a licensed proprietary preparation, but is routinely available as a "special"

Prescribing Notes:

Available in 0.1%, 0.25%, 0.5%, 1% and 2% strengths.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/5984.htm#_5984

Prescribing Notes:

This is not available as a licensed proprietary preparation, but is routinely available as a "special"

Prescribing Notes:

This is not available as a licensed proprietary preparation, but is routinely available as a "special"

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/106484.htm

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/70055.htm

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/5990.htm

Restrictions: Restricted to specialist use only. Restricted to hospital use under specialist dermatological supervision.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/5995.htm

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/5943.htm#_5943

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/PHP7710-calcipotriol-non-proprietary.htm#PHP7710-calcipotriol-non-proprietary

Prescribing Notes:

Calcipotriol and betamethasone can be supplied as individual preparations, calcipotriol 50microgram/g ointment plus betamethasone 0.05% (Diprosone^®) ointment, at a significantly reduced cost. A suggested regimen of the separate preparations may be calcipotriol applied in the morning with application of betamethasone at night.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/106478.htm

Restrictions: Restricted to use under specialist dermatological supervision

Prescribing Notes:

Can be used for severe atopic dermatitis or severe psoriasis when conventional therapy has failed.

Prescribe by brand name.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/4783.htm

Restrictions: Restricted to use under specialist dermatological supervision.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/6002.htm

Restrictions: Restricted to initiation by physicians experienced in the management of eczema. It is restricted to the management of moderate eczema on the face and neck of children aged between 2 years and 16 years that has not been controlled by topical steroids or where there is serious risk of important adverse effects from further topical steroid use, particularly irreversible skin atrophy.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/119691.htm

Restrictions: Topical tacrolimus is restricted to initiation and review by a dermatologist.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/119635.htm

Restrictions:

Restrictions apply as per prescribing notes below.

Prescribing Notes:

Formulary indications:

• Treatment of chronic plaque psoriasis is restricted to specialist use only in patients with severe disease as defined by a total Psoriasis Area Severity Index (PASI) score of >10 and a Dermatology Life Quality Index (DLQI) of >10.
• Treatment of moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy is restricted to specialist use only.

For use in other indications, see sections 1.5.3, 11.8 and 10.1.3.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/128230.htm

Restrictions: The treatment of moderate to severe chronic plaque psoriasis in adults patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) is restricted to specialist use only.

Prescribing Notes:

For other indications please see chapter 10.1.3

Restrictions:

Restricted to specialist use only in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate, or have failed and who are considered unsuitable for biologic therapy given they current disease state or personal preference,

Restrictions:

The use in the treatment of moderate-to-severe atopic dermatitis in adults is restricted to use in accordance with local guidelines in patients who have had an inadequate response to existing systemic immunosuppressants such as ciclosporin, or in whom such treatment is considered unsuitable.

Restrictions:

Restricted to specialist use only.

• Use for adults with psoriasis is restricted to initiation and supervision only by specialist physicians in accordance with NICE Technology Appraisal 103. 
• Use for the treatment of chronic severe plaque psoriasis in children and adolescents is restricted to specialist use in patients where the disease:
  • is severe as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10,
  • has failed to respond to standard systemic therapies or the patient is intolerant to, or has a contraindication to these treatments,
• Etanercept should be discontinued in patients whose psoriasis has not responded adequately at 12 weeks.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/201652.htm

Restrictions:

Restricted to specialist use only. Treatment of severe plaque psoriasis in adults is restricted to specialist use in patients who failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapy including ciclosporin, methotrexate or psoralen ultraviolet A (PUVA) and in accordance with the local approved protocol.

Prescribing Notes:

Infliximab should be prescribed by brand name. Inflectra^® is the preferred biosimilar.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/201653.htm

Restrictions:

Restricted to specialist use in patients with moderate to severe plaque psoriasis who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments

Prescribing Notes:

For use in psoriatic arthritis, see section 10.1.3

BNF Link: https://www.medicinescomplete.com/#/content/bnf/_143907557

Restrictions: Restricted to specialist use only. Restricted to use under specialist dermatological supervision.

BNF Link: http://bnf.org/bnf/bnf/current/6002.htm

Restrictions: Use for moderate to severe plaque psoriasis in adults is restricted to specialist use in patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to or have contraindications to these treatments.

Restrictions:

Restricted to specialist use in accordance with the prescribing notes below.

Prescribing Notes:

Psoriasis in adults:

• The treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA) is restricted to specialist use. Continued treatment should be restricted to patients who achieve a PASI 75% response within 16 weeks.

Psoriasis in adolescents:

• The treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies is restricted to specialist use.  Continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.

For use in psoriatic arthritis see section 10.1.3 and for use in Crohn's disease see section 1.5.3

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/PHP7789-ustekinumab.htm?q=ustekinumab&t=search&ss=text&p=1#_hit